🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,97 USD

Máx. histórico

89,55

118 días

Caída desde máximo

-22,98%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+1,25%

Cierre anterior

68,12

Rango de hoy

66,87 – 70,11

Volumen hoy

1.266.047

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 16 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
27/06/2018 32,20 32,77 31,38 31,72 -2,34% 4,32% 1.169.100
26/06/2018 33,88 33,96 31,41 32,48 -3,85% 7,53% 1.712.200
25/06/2018 35,33 35,73 33,17 33,78 -6,19% 7,25% 1.166.200
22/06/2018 36,42 36,69 34,94 36,01 -0,83% 4,80% 2.015.900
21/06/2018 35,13 36,92 34,58 36,31 +1,88% 6,66% 1.600.700
20/06/2018 35,00 38,33 33,31 35,64 +7,22% 14,34% 6.755.600
19/06/2018 47,69 50,81 32,26 33,24 -30,58% 38,90% 10.788.700
18/06/2018 49,54 52,95 44,50 47,88 +27,51% 17,06% 12.064.400
15/06/2018 38,31 39,04 37,34 37,55 -2,19% 4,44% 1.322.900
14/06/2018 38,00 38,57 37,30 38,39 +1,59% 3,34% 1.056.700
13/06/2018 38,00 38,29 37,19 37,79 -0,45% 2,89% 549.700
12/06/2018 37,91 38,52 37,68 37,96 +0,03% 2,22% 588.000
11/06/2018 37,25 38,17 36,69 37,95 +2,24% 3,97% 738.800
08/06/2018 36,13 37,64 35,78 37,12 +2,03% 5,16% 552.300
07/06/2018 36,19 36,82 35,69 36,38 +0,28% 3,14% 515.300
06/06/2018 36,85 37,06 35,83 36,28 -1,33% 3,34% 421.700
05/06/2018 36,76 37,21 36,57 36,77 +0,05% 1,74% 514.900
04/06/2018 36,10 37,04 34,51 36,75 +1,77% 7,01% 888.400
01/06/2018 34,40 36,85 34,40 36,11 +6,52% 7,12% 1.774.900
31/05/2018 32,05 34,23 31,78 33,90 +6,10% 7,64% 1.212.300
30/05/2018 31,00 32,02 31,00 31,95 +3,16% 3,27% 775.300
29/05/2018 30,57 31,26 30,24 30,97 +0,55% 3,34% 530.400
25/05/2018 30,08 30,89 29,54 30,80 +2,63% 4,49% 578.100
24/05/2018 29,48 30,15 29,34 30,01 +1,28% 2,75% 479.100
23/05/2018 29,88 30,17 29,54 29,63 -1,10% 2,11% 383.900
22/05/2018 30,46 30,67 29,93 29,96 -1,83% 2,43% 410.400
21/05/2018 32,07 32,34 30,42 30,52 -4,60% 6,00% 524.700
18/05/2018 31,63 32,58 31,33 31,99 +1,43% 3,95% 966.100
17/05/2018 31,14 31,86 31,10 31,54 +1,51% 2,44% 621.000
16/05/2018 31,01 31,35 29,82 31,07 +3,50% 4,93% 1.489.800